West Pharmaceutical Services financials
$376.63+0.26%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.07B | $2.89B | $2.95B | $2.89B | $2.83B | $2.15B | $1.84B | $1.72B | $1.60B | $1.51B |
| Gross profit | $1.10B | $998.5M | $1.13B | $1.14B | $1.18B | $767.8M | $605.7M | $545.4M | $512.9M | $501.4M |
| Gross margin | 35.9% | 34.5% | 38.3% | 39.4% | 41.5% | 35.8% | 32.9% | 31.8% | 32.1% | 33.2% |
| Operating income | $636.1M | $590.9M | $707.4M | $734.0M | $752.3M | $406.9M | $296.6M | $240.3M | $225.8M | $195.2M |
| Net income | $493.7M | $492.7M | $593.4M | $585.9M | $661.8M | $346.2M | $241.7M | $206.9M | $150.7M | $143.6M |
| Net margin | 16.1% | 17.0% | 20.1% | 20.3% | 23.4% | 16.1% | 13.1% | 12.0% | 9.4% | 9.5% |
| Diluted EPS | $6.79 | $6.69 | $7.88 | $7.73 | $8.67 | $4.57 | $3.21 | $2.74 | $1.99 | $1.91 |
| EBITDA | $807.5M | $746.3M | $844.7M | $854.6M | $874.6M | $516.0M | $400.0M | $344.7M | $322.5M | $285.9M |
| Operating cash flow | $754.8M | $653.4M | $776.5M | $724.0M | $584.0M | $472.5M | $367.2M | $288.6M | $263.3M | $219.4M |
| Free cash flow | $468.9M | $276.4M | $414.5M | $439.4M | $330.6M | $298.1M | $240.8M | $183.9M | $132.5M | $49.2M |
| Diluted shares | 72.7M | 73.7M | 75.3M | 75.8M | 76.3M | 75.8M | 75.4M | 75.4M | 75.8M | 75.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $791.3M | $484.6M | $853.9M | $894.3M | $762.6M | $615.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $202.8M | $202.6M | $206.8M | $208.9M | $253.0M | $255.2M |
| Total assets | $4.27B | $3.64B | $3.83B | $3.62B | $3.31B | $2.79B |
| Total liabilities | $1.09B | $961.1M | $948.5M | $931.9M | $978.4M | $939.3M |
| Shareholders' equity | $3.18B | $2.68B | $2.88B | $2.68B | $2.34B | $1.85B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology